{
    "clinical_study": {
        "@rank": "104211", 
        "arm_group": [
            {
                "arm_group_label": "0.033 mg/kg/day", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "0.066 mg/kg/day", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to investigate the long-term\n      efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan\n      syndrome."
        }, 
        "brief_title": "Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Genetic Disorder", 
            "Noonan Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism", 
                "Genetic Diseases, Inborn", 
                "Noonan Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese children with Noonan syndrome clinically diagnosed in one of the following\n             ways: 1. Clinically diagnosed by at least two medical experts using van der Burgt\n             score list, 2. Clinically diagnosed by one medical expert using van der Burgt score\n             list and diagnosed by result of genetic testing for Noonan syndrome, 3. Clinically\n             diagnosed by one medical expert using van der Burgt score list and diagnosed by the\n             same medical expert based on the results of centralised evaluation of facial change\n             using van der Burgt score list\n\n          -  Height SDS (standard deviation score): -2 SDS or below (according to the Japanese\n             reference data)\n\n          -  Age: boys 3 to below 11 years, girls 3 to below 10 years\n\n          -  Height records must be available within the period between 40 and 64 weeks prior to\n             Visit 1 (screening)\n\n          -  Prepubertal children (definition for girls breast and pubes of Tanner stage is I, and\n             none of menses, and for boys testicular volume below 4 mL, and pubes and penis of\n             Tanner stage is I)\n\n        Exclusion Criteria:\n\n          -  Children with known or suspected hypersensitivity against human growth hormone (hGH)\n             or related products (including any components of the trial products)\n\n          -  Children with diabetic type diagnosed with the Japanese Diabetes Society\n             Classification\n\n          -  Children with history or presence of active malignancy\n\n          -  Children who have received GH (growth hormone) treatment\n\n          -  Children who have received systemic administration of the following medications\n             within two years prior to Visit 1 (screening): Thyroid hormone (except replacement\n             therapy), antithyroid hormone, androgen, oestrogen, progesterone, anabolic steroid,\n             adrenocortical steroid treatment period for at least 13 weeks), derivative of\n             gonadotropin releasing hormone and somatomedin C (IGF-I)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927861", 
            "org_study_id": "GHLIQUID-4020", 
            "secondary_id": "U1111-1131-5892"
        }, 
        "intervention": {
            "arm_group_label": [
                "0.033 mg/kg/day", 
                "0.066 mg/kg/day"
            ], 
            "description": "Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.", 
            "intervention_name": "somatropin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Saitama-city, Saitama", 
                    "country": "Japan", 
                    "zip": "336-8522"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in height SDS (Standard Deviation Score)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 104"
            }, 
            {
                "measure": "Change in height SDS (Standard Deviation Score)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 208"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of treatment emergent adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, Week 104"
            }, 
            {
                "measure": "Incidence of treatment emergent adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0, Week 208"
            }, 
            {
                "measure": "Change in IGF-I (insulin like growth factor I)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 104"
            }, 
            {
                "measure": "Change in IGF-I (insulin like growth factor I)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 208"
            }, 
            {
                "measure": "Change in HbA1c (Glycosylated haemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 104"
            }, 
            {
                "measure": "Change in HbA1c (Glycosylated haemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 208"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}